BridgeBio Pharma, Inc. (BBIO) Q2 2025 Earnings Call Transcript

BridgeBio Pharma reported robust Q2 2025 results, with Attruby net product revenue doubling to $71.5 million, driven by accelerated patient additions (120/week) and expanding prescriber adoption, particularly in treatment-naive patients. The company emphasized Attruby's clinical differentiation, including its impact on serum TTR levels, variant subtypes, and AFib, alongside its accessible patient programs. Strategically, BridgeBio is poised to become a diversified biopharma, with three significant Phase III readouts anticipated in ADH1 and LGMD2I (Fall 2025), and achondroplasia (early 2026), each representing potential multi-billion dollar opportunities and leveraging the commercial infrastructure built by Attruby. The company concluded the quarter with a strong cash position of $756.9 million, extending its runway through these key value-creating milestones.

Analysis

BridgeBio Pharma delivered a strong Q2 2025, primarily driven by the accelerating commercial launch of its ATTR-CM therapy, Attruby. The drug generated $71.5 million in U.S. net sales, representing 100% quarter-over-quarter growth, significantly outperforming internal projections. This momentum is supported by an increase in new patient additions to approximately 120 per week, up from 100 per week, with total unique patient prescriptions reaching 3,751. The growth is concentrated in the critical treatment-naive patient segment, where the company estimates it is capturing 18-20% of new prescriptions. Management attributes this success to a differentiated clinical profile, highlighting recent publications that link Attruby's superior TTR stabilization to improved outcomes, including a 59% risk reduction in the high-risk V122I variant population and a 43% reduction in cardiovascular hospitalizations for patients with AFib. This clinical differentiation is complemented by an aggressive commercial strategy focused on accessibility, with nearly 90% of patients reportedly paying $0 out-of-pocket.

Beyond Attruby, the company is at a strategic inflection point, positioning itself for a transition into a diversified biopharmaceutical entity. The near-term pipeline holds three pivotal, potentially billion-dollar catalysts: Phase III data for encaleret in ADH1 and for its LGMD2I therapy are expected in Fall 2025, with data for infigratinib in achondroplasia to follow in early 2026. The company's financial position appears robust, with a cash balance of $756.9 million, which management states is sufficient to fund operations through these value-creating milestones, mitigating near-term financing risk.

Key Decisions for Investors

• Investors should closely monitor Attruby's weekly prescription trends, particularly new-to-therapy starts, to verify if the reported acceleration to 120 patients per week is sustainable and can drive further market share gains against Pfizer and Alnylam.
• The primary focus should be on the upcoming Phase III results for encaleret (ADH1) and the LGMD2I program in Fall 2025, as these are the most significant near-term catalysts with the potential to fundamentally re-rate the company's valuation and diversify its revenue base.
• It is prudent to track the evolution of gross-to-net deductions for Attruby, as the current reliance on generous patient assistance programs could impact long-term profitability, even as it drives impressive top-line growth.
• Given the competitive landscape, investors should monitor for strategic responses from Pfizer and Alnylam, including potential pricing adjustments or new data releases, which could alter the dynamics of the rapidly expanding ATTR-CM market.